S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
All the trading advice you’ve ever received boils down to this (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
All the trading advice you’ve ever received boils down to this (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
All the trading advice you’ve ever received boils down to this (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
All the trading advice you’ve ever received boils down to this (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
All the trading advice you’ve ever received boils down to this (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
All the trading advice you’ve ever received boils down to this (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
All the trading advice you’ve ever received boils down to this (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
All the trading advice you’ve ever received boils down to this (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
All the trading advice you’ve ever received boils down to this (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
All the trading advice you’ve ever received boils down to this (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
All the trading advice you’ve ever received boils down to this (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
All the trading advice you’ve ever received boils down to this (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Revance Therapeutics Stock Price, News & Analysis (NASDAQ:RVNC)

$7.09
+0.04 (+0.57%)
(As of 12/7/2023 ET)
Compare
Today's Range
$6.93
$7.20
50-Day Range
$5.81
$11.47
52-Week Range
$5.72
$37.98
Volume
1.16 million shs
Average Volume
1.62 million shs
Market Capitalization
$622.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.33

Revance Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
257.3% Upside
$25.33 Price Target
Short Interest
Bearish
16.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.05) to ($2.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

205th out of 960 stocks

Pharmaceutical Preparations Industry

53rd out of 381 stocks


RVNC stock logo

About Revance Therapeutics Stock (NASDAQ:RVNC)

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

RVNC Stock Price History

RVNC Stock News Headlines

Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
What 10 Analyst Ratings Have To Say About Revance Therapeutics
Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
Q3 2023 Revance Therapeutics Inc Earnings Call
Revance down 16% as investor day update fails to impress
What's Going On With Botox Rival Revance Therapeutics' Stock Today?
Revance Provides Corporate Update at Investor Day
Revance's FDA Nod: Beauty, Brains, And Balance Sheets
Revance to Host Investor Day on September 19, 2023
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVNC
Employees
534
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.33
High Stock Price Target
$42.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+257.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-356,420,000.00
Net Margins
-193.42%
Pretax Margin
-193.28%

Debt

Sales & Book Value

Annual Sales
$214.16 million
Book Value
$0.15 per share

Miscellaneous

Free Float
84,652,000
Market Cap
$622.59 million
Optionable
Optionable
Beta
0.83
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report














RVNC Stock Analysis - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVNC shares.
View RVNC analyst ratings
or view top-rated stocks.

What is Revance Therapeutics' stock price target for 2024?

8 Wall Street research analysts have issued 1-year price objectives for Revance Therapeutics' shares. Their RVNC share price targets range from $12.00 to $42.00. On average, they anticipate the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 257.3% from the stock's current price.
View analysts price targets for RVNC
or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2023?

Revance Therapeutics' stock was trading at $18.46 on January 1st, 2023. Since then, RVNC shares have decreased by 61.6% and is now trading at $7.09.
View the best growth stocks for 2023 here
.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RVNC earnings forecast
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.28. The biopharmaceutical company had revenue of $56.78 million for the quarter, compared to the consensus estimate of $58.49 million. Revance Therapeutics had a negative net margin of 193.42% and a negative trailing twelve-month return on equity of 903.28%.

What ETFs hold Revance Therapeutics' stock?

ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Polar Capital Holdings Plc (4.74%), Invesco Ltd. (3.31%), FMR LLC (2.16%), Rubric Capital Management LP (1.82%), Rubric Capital Management LP (1.82%) and Wellington Management Group LLP (1.23%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RVNC) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -